Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication
about
The Epstein-Barr virus replication protein BBLF2/3 provides an origin-tethering function through interaction with the zinc finger DNA binding protein ZBRK1 and the KAP-1 corepressorRoscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factorsPhosphoproteomic analyses reveal signaling pathways that facilitate lytic gammaherpesvirus replicationAntiviral activity of CYC202 in HIV-1-infected cellsMeta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformationIn vivo dynamics of EBNA1-oriP interaction during latent and lytic replication of Epstein-Barr virus.Homologous recombinational repair factors are recruited and loaded onto the viral DNA genome in Epstein-Barr virus replication compartments.Noise cancellation: viral fine tuning of the cellular environment for its own genome replication.Increased efficiency of phorbol ester-induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus during S phaseRoscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenanceEpstein-Barr virus BGLF4 kinase retards cellular S-phase progression and induces chromosomal abnormality.Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes.Phosphorylation of MCM4 at sites inactivating DNA helicase activity of the MCM4-MCM6-MCM7 complex during Epstein-Barr virus productive replication.Cell cycle modulation by Marek's disease virus: the tegument protein VP22 triggers S-phase arrest and DNA damage in proliferating cells.Kaposi's sarcoma-associated herpesvirus-encoded protein kinase and its interaction with K-bZIP.Epstein-Barr virus BGLF4 kinase induces premature chromosome condensation through activation of condensin and topoisomerase II.Cardiac Nav 1.5 is modulated by ubiquitin protein ligase E3 component n-recognin UBR3 and 6.Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.Characterization of histone post-translational modifications during virus infection using mass spectrometry-based proteomics.Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1Regulation of the retinoblastoma proteins by the human herpesviruses.Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin.Potential of protein kinase inhibitors for treating herpesvirus-associated disease.Regulatory network analysis of Epstein-Barr virus identifies functional modules and hub genes involved in infectious mononucleosis.Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways.Nuclear transport of Epstein-Barr virus DNA polymerase is dependent on the BMRF1 polymerase processivity factor and molecular chaperone Hsp90Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human MacrophagesCyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles.Mutation of a single amino acid residue in the basic region of the Epstein-Barr virus (EBV) lytic cycle switch protein Zta (BZLF1) prevents reactivation of EBV from latency.KSHV G protein-coupled receptor inhibits lytic gene transcription in primary-effusion lymphoma cells via p21-mediated inhibition of Cdk2.Varicella-zoster virus IE63 protein phosphorylation by roscovitine-sensitive cyclin-dependent kinases modulates its cellular localization and activity.Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu miceEpstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment.Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.Phosphorylation of p27Kip1 by Epstein-Barr virus protein kinase induces its degradation through SCFSkp2 ubiquitin ligase actions during viral lytic replication.
P2860
Q24558692-D9C4DF11-57C2-4505-8AF8-1253DE725E2CQ24562983-ECF8DADC-1B76-46EC-B47D-48AE88BE2C38Q27333727-5ABD978F-A575-4608-99F0-55BA77CB97D3Q28292152-D42249C3-926F-45D7-8A57-B3B2E80EF146Q30844939-3929E522-A4B6-45A0-A0AA-DE987CE436E1Q31122638-0D621A16-7784-4D6C-8EC8-AAC71A32EC95Q33433812-2789A8D7-C83B-49B6-ADF1-1F88D2938A6DQ33780955-FD477C3D-D27D-4B4F-B96F-1A301AD33AE5Q33781299-1E1BFABF-6666-4212-BC41-51E3667FEE06Q33786506-5767F215-E2E8-442D-9A7A-D9FA8B2C47D1Q34328083-385AD20C-F304-4A5D-8E23-7B0A84FF8AEEQ34869625-B7B0AD31-4906-4AA3-AA4E-74802C4C5652Q35101480-4C12D3A0-9ED9-4744-BD80-B7E4B44A5A4BQ35191413-BA12274D-70D4-4A7E-9DCB-DF74530F98D8Q35635192-D24CE352-6C95-471B-B167-822F6E183559Q35857467-F0FB7F84-074C-4E9B-A933-991E353927EFQ36057480-9D632144-223E-4DD7-B7D2-D1F5024C9932Q36296415-785C3327-74EB-46BE-A1C2-E34AADB8CEBEQ36304966-E635DA49-C7D1-4B6F-AAFA-23C7DD689AC4Q36716750-D5ACA94E-3AA7-4A5C-B6D4-22B07B9C847FQ36956909-ABB314C0-6D53-46C2-9E2B-D79952248916Q37085853-774B70F5-A8A0-49AE-9A9C-DBDAC54E0C7EQ37566280-D9CFE37E-015C-4910-B671-7B00E74CF3E8Q38100859-439D05C9-D1AF-40A3-8D8F-303FC66532BBQ38437452-23B3EA2A-B52E-4669-AF84-87DEA4DB7E70Q38862080-382A3345-3297-4686-8003-9DD5D4D13FDFQ39440772-2CF6C360-A707-445C-BF31-411B84870719Q39530544-F18716BA-A800-46DD-98D8-DAB5D28E3F90Q40274359-E71A9468-BCE4-40BE-8A1B-A34102EE2841Q40361558-43AF5E57-472D-4214-9155-963B349D1466Q40375800-1EC6A4A4-506B-4DE8-A4B4-891D51721C5BQ40409988-B803B402-7535-4218-B2FB-AB498CBD70CEQ40444868-74793B46-ADB7-48BC-A9AE-4FCE4DEF1ADEQ40478598-29F4FEFC-77C2-47CD-98A0-9C61FAE7A91EQ41770253-2ECF2367-14AD-44BE-89E8-EEE2C0AEC850Q42122796-77648FB3-7869-4CF3-B487-E28357568076Q43099184-C6F5511D-BEEC-49F2-8F8D-EA95F665BFDB
P2860
Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@ast
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@en
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@nl
type
label
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@ast
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@en
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@nl
prefLabel
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@ast
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@en
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@nl
P2093
P2860
P1433
P1476
Inhibition of S-phase cyclin-d ...... enting viral lytic replication
@en
P2093
Ayumi Kudoh
Hiroki Isomura
Tatsuya Tsurumi
Tohru Daikoku
Tohru Kiyono
Yukihiro Nishiyama
Yutaka Sugaya
P2860
P304
P356
10.1128/JVI.78.1.104-115.2004
P407
P577
2004-01-01T00:00:00Z